Mission Statement, Vision, & Core Values of IDEAYA Biosciences, Inc. (IDYA)

IDEAYA Biosciences Inc. (IDYA) is dedicated to precision medicine oncology, but what exactly drives this commitment? Understanding their mission, vision, and core values provides insight into the company's strategic direction and daily operations, especially as they navigate the complexities of targeted therapeutics development.

With approximately $1.1 billion in cash, cash equivalents, and marketable securities as of December 31, 2024, compared to $632.6 million as of December 31, 2023, IDEAYA is well-positioned to fund operations into at least 2028. But how does this financial stability translate into achieving their long-term goals, and what principles guide their decision-making as they strive to improve patient outcomes in the competitive field of oncology?

IDEAYA Biosciences, Inc. (IDYA) An Overview of

IDEAYA Biosciences, Inc. (IDYA) is a biopharmaceutical company focused on discovering and developing targeted therapeutics for patient populations selected using molecular diagnostics. Founded with the goal of translating cutting-edge research into clinical breakthroughs, IDEAYA has built a pipeline of oncology-focused programs. As of April 2025, IDEAYA continues to advance its research and development efforts, seeking to address unmet needs in cancer treatment. IDEAYA is dedicated to delivering innovative therapies that improve the lives of patients with cancer.

In the latest financial reports, IDEAYA Biosciences, Inc. showcased robust financial performance, driven significantly by its strategic focus on targeted therapeutics. While specific record-breaking revenue figures and market growth percentages are best verified in their official 2024 fiscal year reports, the company has demonstrated a strong trajectory in its financial health, particularly noting milestones in product development and strategic collaborations. These advancements underscore IDEAYA's commitment to innovation and its potential for sustained growth in the competitive biopharmaceutical landscape. For detailed financial specifics, refer directly to IDEAYA's official financial statements.

IDEAYA Biosciences, Inc. is emerging as a notable company in the biopharmaceutical industry, particularly known for its precision medicine approach to cancer treatment. To further understand IDEAYA’s mission, vision, core values, and the factors driving its success, explore additional insights:

IDEAYA Biosciences, Inc. (IDYA) Mission Statement

IDEAYA Biosciences, Inc. (IDYA) is a precision medicine oncology company focused on the discovery and development of targeted therapeutics. IDEAYA's mission is passionately pursuing the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.

IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.

IDEAYA's mission is supported by a world-class team of leading scientists and advisors with extensive knowledge and expertise in cancer biology, small molecule drug discovery, translational biology, and clinical development.

IDEAYA's most advanced pipeline programs include:

• Darovasertib (IDE196): A clinical-stage PKC inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.
• IDE397: A clinical-stage MAT2A inhibitor targeting patients with tumors having MTAP gene deletion, which represents approximately 15% of solid tumors.
• IDE161: A clinical-stage PARG inhibitor for patients having tumors with homologous recombination deficiency (HRD).

IDEAYA is headquartered in South San Francisco, California.

As of Q3 2024, IDEAYA Biosciences had $1.2 billion of cash, cash equivalents, and marketable securities, which is anticipated to fund operations into at least 2028. In July 2024, IDEAYA completed an oversubscribed follow-on financing of approximately $302.4 million.

IDEAYA's financial performance includes:

• Market Cap (as of Q4 2023): $486.2 million
• Annual Revenue (2022): $47.3 million
• Net Loss (2022): $86.4 million
• Cash and Investments (Q3 2023): $292.1 million

IDEAYA has established strategic collaborations with GSK, Merck, Pfizer, and Gilead but wholly-owns or controls its four most-advanced clinical programs and we are committed to building a best-in-industry organization to deliver our precision medicines to the people who need them.

IDEAYA was founded with the premise that attracting the industry's best scientists and focusing on areas of transformative research is a proven model for delivering game-changing medicines to patients. As an organization, we have an entrepreneurial spirit, a commitment to foster innovation, and a passion to discover and develop innovative new therapies for cancer patients.

IDEAYA is a clinical-stage precision medicine oncology company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality – an emerging class of precision medicine targets.

For additional information, you can visit: IDEAYA Biosciences, Inc. (IDYA): History, Ownership, Mission, How It Works & Makes Money

IDEAYA Biosciences, Inc. (IDYA) Vision Statement of

IDEAYA Biosciences, Inc. (IDYA) is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Understanding the mission, vision, and core values provides a comprehensive view of the company's strategic direction and operational philosophy. These elements guide IDEAYA's actions and help stakeholders understand its long-term goals and priorities.

IDEAYA Biosciences' mission is focused on discovering and developing targeted therapeutics for cancer patients. This involves:

• Identifying patient populations through the use of molecular diagnostics.
• Creating innovative therapies that address unmet needs in oncology.
• Advancing precision medicine to improve treatment outcomes.

This mission statement highlights the company's commitment to precision medicine and its focus on developing targeted therapies that cater to specific patient subgroups identified through molecular diagnostics. As of the fiscal year 2024, IDEAYA has been actively pursuing this mission through various research and development programs.

While a specific, concise vision statement for IDEAYA Biosciences is not explicitly available, the company's actions and communications suggest a vision centered around becoming a leader in precision medicine oncology. This vision encompasses:

• Pioneering new approaches in targeted cancer therapy.
• Establishing a robust pipeline of innovative drug candidates.
• Delivering significant improvements in patient outcomes through personalized treatments.

In alignment with this vision, IDEAYA Biosciences has made significant strides. For example, in 2024, IDEAYA Biosciences reported a cash, cash equivalents and marketable securities balance of $444.7 million. This positions the company strongly to continue investment in research and development. This vision aligns with their strategic collaborations and clinical advancements. The company's focus on innovative drug candidates and personalized treatments underscores its commitment to improving patient outcomes.

IDEAYA Biosciences' core values are integral to its operational culture and strategic initiatives. Although not explicitly listed, these values can be inferred from the company's activities and public statements:

• Innovation: Emphasizing the development of novel therapeutic approaches.
• Precision: Focusing on targeted treatments based on molecular diagnostics.
• Collaboration: Partnering with other organizations to advance research and development.
• Integrity: Maintaining high ethical standards in all activities.
• Patient-Centricity: Prioritizing the needs and outcomes of patients.

These core values are reflected in IDEAYA's collaborations, such as the one with Amgen, which focuses on developing novel therapeutics. IDEAYA's commitment to innovation is further demonstrated by its pipeline of drug candidates targeting specific genetic mutations and pathways in cancer.

IDEAYA Biosciences' strategic focus is evident in its approach to precision medicine, aiming to develop treatments that are both effective and tailored to the individual patient. The company's financial stability, with a solid balance sheet, supports its ongoing research and development efforts.

To gain more insights into the investors' perspective, you might find this link helpful: Exploring IDEAYA Biosciences, Inc. (IDYA) Investor Profile: Who’s Buying and Why?

IDEAYA Biosciences, Inc. (IDYA) Core Values of

While specific details on IDEAYA Biosciences, Inc.'s (IDYA) mission statement, vision, and core values are not explicitly available, we can infer some of their guiding principles based on their activities and focus areas. IDEAYA is dedicated to discovering and developing targeted therapeutics for patient populations selected using molecular diagnostics.

Here are potential core values exemplified by IDEAYA's actions:

Innovation:

IDEAYA operates at the forefront of cancer research, focusing on innovative approaches to drug discovery and development. Evidenced by:

• Their focus on synthetic lethality, a cutting-edge approach in cancer therapy.
• The development of first-in-class or best-in-class therapeutics targeting unmet needs in oncology.
• The utilization of molecular diagnostics to precisely select patient populations.

Commitment to Patients:

IDEAYA's ultimate goal is to improve the lives of cancer patients. This is reflected in:

• Their focus on developing targeted therapies that are more effective and have fewer side effects.
• Their dedication to identifying and addressing unmet needs in specific cancer subtypes.
• Their partnerships with patient advocacy groups to ensure that patient perspectives are incorporated into their research and development efforts.

Scientific Excellence:

IDEAYA places a high value on rigorous scientific research and data-driven decision-making. This is demonstrated by:

• Their team of experienced scientists and drug developers.
• Their collaborations with leading academic institutions and research organizations.
• Their commitment to publishing their research findings in peer-reviewed journals.

Collaboration:

IDEAYA recognizes that collaboration is essential for success in the complex field of drug development. This is reflected in:

• Their strategic partnerships with pharmaceutical companies, such as GSK, to accelerate the development and commercialization of their therapies.
• Their collaborations with academic researchers to advance scientific understanding of cancer biology.
• Their engagement with patient advocacy groups to ensure that their work is aligned with patient needs.

For insights into IDEAYA Biosciences, Inc.'s financial health, explore Breaking Down IDEAYA Biosciences, Inc. (IDYA) Financial Health: Key Insights for Investors.